• Iovance Biotherapeutics schedules virtual annual stockholder meeting for June 10, 2026.
• Ballot includes election of six directors, including Iain Dukes, Athena Countouriotis, Ryan Maynard.
• Stockholders to vote on advisory approval of named executive officer pay.
• Separate advisory vote to set frequency of future say-on-pay votes.
• Items also include proposal to raise authorized common shares to 650,000,000 from 500,000,000.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Iovance Biotherapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-044958), on April 17, 2026, and is solely responsible for the information contained therein.